We partner with a secure submission system to handle manuscript submissions.
Please note:
You will need an account for the submission system, which is separate to your Cambridge Core account. For login and submission support, please visit the
submission and support pages.
Please review this journal's author instructions, particularly the
preparing your materials
page, before submitting your manuscript.
Click Proceed to submission system to continue to our partner's website.
To save this undefined to your undefined account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your undefined account.
Find out more about saving content to .
To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Hospitals may not preserve the assumptions approved for medical-equipment purchases alongside post-adoption financial and value outcomes. We specified a clinical service line (CSL) investment recovery framework and examined its initial feasibility using routine hospital records.
Methods
Targeted mapping of health technology assessment (HTA), lifecycle HTA, management accounting, and organizational learning concepts was followed by internal logic checks. A retrospective records-based application was conducted for one purposively selected 4 K arthroscopy camera-head investment at a Japanese acute-care hospital. Aggregate fixed-asset, lease, and claims records were analyzed descriptively without patient-level data or causal attribution.
Results
The framework links CSL definition, pre-adoption commitments, annualized investment burden (AIB), contribution margin (CM), evidence status, allocation, value guardrails, and feedback. The 72-month lease had a total value of JPY 4,728,240 and a minimum documented annual burden of JPY 788,040. Shoulder arthroscopy volume increased from 220 to 245 procedures (11.4 percent), and nominal procedure-fee revenue increased from JPY 102.8 million to JPY 114.9 million (11.8 percent) between 12-month periods. Planned values, variable costs, direct use logs, and prespecified quality or access indicators were unavailable; CM-based recovery metrics could not be calculated. The documented annual burden equaled JPY 31,522 per observed additional procedure, or 6.52 percent of the observed revenue increase under full attribution.
Conclusions
The framework operationalizes hospital-level post-adoption and lifecycle HTA as an auditable CSL process. The application demonstrated partial data availability and identified fields that must be preserved prospectively; it did not establish causality, actual recovery, acceptability, or decision impact.
Orphan drug reimbursement remains a contested area in health technology assessment (HTA), as decision makers must balance limited evidence, high unmet need, patient-relevant value, and affordability. Multi-criteria decision analysis (MCDA) has been proposed to make such trade-offs more explicit and transparent, yet empirical applications in European national HTA settings remain scarce.
Methods
We developed and piloted an MCDA framework for orphan drug reimbursement in Belgium. Candidate criteria were identified through a systematic literature review. A multidisciplinary expert panel (comprising representatives from the national reimbursement agency, sickness funds, patient organizations, pharmaceutical companies, clinicians, and bioethicists) participated in four focus group discussions to select and define criteria. Criterion weights were elicited through a three-round Delphi process. The framework was piloted on four orphan drugs previously appraised in Belgium: ponatinib, pirfenidone, onasemnogene abeparvovec, and metreleptin.
Results
Seven quantitative and three qualitative contextual criteria were selected. Unmet medical need received the highest weight, followed by comparative effectiveness and impact on patient-reported outcomes. Onasemnogene abeparvovec achieved the highest overall MCDA score (0.77), followed by metreleptin (0.65), pirfenidone (0.47), and ponatinib (0.39). The pilot also generated policy-relevant insights on criterion design, handling residual uncertainty, separating value assessment from reimbursement feasibility (through cost criteria), and using scores to support–rather than replace–deliberation.
Conclusion
This study presents the first MCDA framework for orphan drug reimbursement in Belgium and illustrates how criterion weights and scores can structure committee deliberation, complemented by contextual appraisal, to support more transparent, consistent, and accountable decision making.
We examined long-term treatment-effect patterns relevant to treatment effect waning (TEW) modeling in oncology health technology assessment (HTA), compared the dispersion and update stability of hazard ratios (HRs) and restricted mean survival time ratios (RMSTRs), and developed prediction models to support extrapolation model selection and TEW modeling.
Methods
Using the FDA Hematology/Oncology Approvals Database, we identified phase II/III randomized controlled trials (2006-2025) with updates. We included overall survival (OS) and other time-to-event end points (non-OS). We conducted 2/3/4/5-year landmark analyses to estimate post-landmark HRs and RMSTRs, summarized by event-weighted medians and dispersion (coefficient of quartile relative dispersion, CQR). Update-related change was quantified using updated-to-initial ratios. We predicted longer-term RMSTR using elastic-net regression with nested cross-validation and split-conformal 90 percent prediction intervals.
Results
We analyzed 168 trials (270 contrasts; 150 OS, 120 non-OS). Across landmark analyses at 2, 3, 4, and 5 years, RMSTR was consistently less dispersed than HR for both OS and non-OS end points, while post-landmark HRs generally remained < 1. Update ratios were more stable for RMSTR than HR. Initial and updated RMSTR were strongly correlated (OS r = .87; non-OS r = .82). Parsimonious regularized models accurately predicted updated RMSTR, with conformal prediction intervals achieving 91 percent and 96 percent coverage for OS and non-OS.
Conclusions
Reliance on current HR-based TEW modeling practices alone may be insufficient to fully characterize long-term treatment-effect uncertainty. RMSTR was consistently less dispersed than HR and predictable from early trial data, providing an anchor for extrapolation model selection and TEW uncertainty analysis in oncology economic evaluations.
Health technology assessment (HTA) is a multidisciplinary approach that evaluates the clinical data and cost-effectiveness of health technologies within broader policy and societal contexts. This study aimed to identify barriers and facilitators to conducting HTA and implementing its findings in Jordan and to determine key technical and context-specific priorities to enhance HTA use.
Methods
A cross-sectional study was conducted using an online, self-administered questionnaire distributed between 1 June and 29 July 2024. Participants were purposively sampled and invited via email. The questionnaire’s face and content validity were assessed by two local experts. Responses from researchers and decision-makers were analyzed descriptively.
Results
A total of fifty-one participants were included. Both groups identified “lack of routinely collected local effectiveness data and national health statistics” and “absence of health state preference values for estimating quality-adjusted life-years (QALYs)” as major barriers to conducting HTA. The top-rated facilitator was “the development of a good-quality national real-world database.” Researchers additionally highlighted “financial incentives for particular interventions” as an important barrier, whereas decision-makers emphasized “the lack of formal willingness-to-pay thresholds” as the primary barrier to HTA implementation. Both groups identified “prioritization of economic evaluations targeting high-burden conditions” as the most important facilitator for implementation.
Conclusions
Significant systemic and methodological barriers hinder HTA conduct and implementation in Jordan – including limited local data, a lack of health state preference values, and the absence of explicit willingness-to-pay thresholds. Strengthening national data infrastructure, establishing clear policy frameworks, and prioritizing economic evaluations are critical for enhancing HTA integration and supporting evidence-informed decision-making.
Variability in methodology and pricing across country-specific health economic evaluation (EE) guidelines hampers cross-national transferability. Guideline updates can also impede generalizability within countries over time. This study empirically illustrates how changes in reference prices impact cost analysis within (partial) EEs, using the economic burden of adolescent idiopathic scoliosis (AIS) in the Netherlands and the United Kingdom (UK).
Methods
Country-specific databases were used to estimate costs to compare within- and cross-country EE guidelines. Reference prices from the Dutch (2014 and 2024) and UK (2021/2022 and 2022/2023) guidelines were considered, and resource usage was held constant. Costs were indexed (2022) and adjusted using Purchasing Power Parity. Societal cost per AIS patient, share attributions, and unit costs between EE guidelines were compared.
Results
Within-country comparisons indicated societal cost increases in the Netherlands (18 percent) and the UK (1 percent). Following a Dutch guideline update, twelve cost items changed by >10 percent, compared with four did in the UK update. UK societal costs were 69 percent higher than in the Netherlands. Ten cost items differed by >100 percent, with generally higher UK costs.
Conclusions
EEs cost analyses are substantially influenced by differences in reference prices across countries. National guideline updates can markedly affect the within-country comparability and generalizability of cost analyses over time. Increased transparency in methods used to derive reference prices is essential to improve transferability and interpretation of EE results. A standardized approach for estimating reference prices could reduce methodological variation, strengthen consistency across jurisdictions, and enhance comparability of international and longitudinal EEs.
The use of surrogate endpoints poses challenges to health technology assessment (HTA) agencies and payers when informing the clinical and cost-effectiveness of health technologies. Decision makers often need to make recommendations in the absence of well-established evidence on their validation, particularly when the surrogate endpoint is novel without clear links to the longer-term outcome. This study explored the guidance needs of HTA agencies and identified how they have considered and dealt with surrogate endpoints in cost-effectiveness analysis.
Methods
A qualitative study was used to explore the professional experiences of international HTA staff and their collaborators. Data were collected using three focus groups with 29 participants representing 20 HTA agencies or associated organizations. Framework analysis was used to identify themes from the transcripts.
Results
HTA agencies frequently see submissions featuring surrogate endpoints. Issues they face include definitional concerns, absent or weak evidentiary links, and resource-intensive validation methods. Versatile guidance that is mindful of these challenges, such as those faced with rare diseases, is required. This would help to clarify expectations and help ascertain the required information from industry for economic modeling, on how to present the uncertainty arising from surrogate endpoints, and how to appropriately report the findings.
Conclusions
Decision making using surrogate endpoints is a frequent and challenging problem faced by HTA agencies. These results provide the first-hand experiences and reflect the needs of HTA agencies globally. The resulting recommendations and considerations for the use of surrogate endpoints in economic modeling should benefit HTA agencies moving forward.
Title/abstract and full-text screening are among the most time-consuming stages of systematic reviews. Large language models (LLMs) such as ChatGPT can assist in screening, but prior evaluations have largely focused on abstract-level decisions and require coding or application programming interfaces (API) access, limiting practical application. This study developed and evaluated a structured, prompt-based approach that enables LLMs to perform both abstract and full-text screening without programming or API integration.
Methods
Using datasets from three completed meta-analyses, we implemented a stepwise training framework involving comprehension checks, criterion-specific feedback, and iterative prompt refinement. Study 1 optimized file format and batch size using 1,000 abstracts and 50 full texts. Studies 2 and 3 validated the approach using independent datasets on teletherapy versus in-person therapy (1,321 abstracts, 82 full texts) and emotion regulation and mental health (1,500 abstracts, 129 full texts), respectively. Human reviewers’ decisions served as the reference standard.
Results
In Study 1, the LLM achieved 98 percent sensitivity and 80.6 percent specificity at abstract screening, with batches of 50 abstracts in plain-text format performing optimally. In Study 2, sensitivity and specificity were 100 percent and 85.6 percent for abstracts, with 82.1 percent full-text accuracy and all eligible studies retained. In Study 3, abstract screening achieved 100 percent sensitivity and 93 percent specificity, while full-text screening achieved 96.2 percent sensitivity and 90.3 percent specificity.
Conclusions
A structured, prompt-based approach enabled LLMs to achieve high sensitivity and specificity across both screening stages without coding or APIs. With human oversight, this accessible workflow can reduce reviewer burden and accelerate evidence synthesis.
To provide methodological enhancement to hospital-based Health Technology Assessment (HTA) by (i) analyzing technical-scientific reports produced by hospital-based HTA (HB-HTA) units and (ii) examining their relation to the identification of unmet medical needs (UMNs).
Methods
This study adopts a qualitative case study design, methodologically enhanced through the analysis of 37 HTA reports – technical-scientific reports (TSRs) – produced by the HTA Unit of the Hospital de Clínicas de Porto Alegre (HCPA), recognized as the leading public hospital in Latin America (according to IntelLat, 2025). Content analysis, guided by international references such as the NEED project, supported the improvement of the evaluation process of TSRs and their related UMNs.
Results
Thirty-nine UMNs were identified across the 37 assessed technologies, predominantly therapeutic (56.8 percent) and diagnostic (32.4 percent), especially in neurology, oncology, and cardiology. Most technologies (89.2 percent) showed additional (Research and Development) R&D needs. The study also demonstrated improvements in the evaluation process of TSRs and the identification of related UMNs.
Conclusions
This study presents a methodological improvement that enables HTA reports to serve as structured sources of institutional intelligence. By identifying UMNs, the approach strengthens the role of HB-HTA in informing future R&D agendas. Replication in other hospital and health system contexts is recommended to consolidate its applicability and broaden its impact.
The objective of this study is to describe the development and first implementation of a protocol for evaluating patient involvement in health technology assessment (HTA) within the Spanish HTA Network (RedETS), establishing a framework for continuous monitoring across agencies.
Methods
A multi-phase process informed protocol development. Indicators were proposed and refined based on international evidence and RedETS experience. Three concise questionnaires were designed for agency leads, HTA coordinators, and patients, and improved through consultation and pilot testing. The first evaluation cycle was conducted in March 2025 via online surveys. Quantitative data were summarized descriptively, and qualitative responses analyzed thematically. A stakeholder meeting reviewed findings.
Results
Responses were received from all eight agencies, the coordinators of all forty-nine HTA reports published during the study period, and ten of the thirty-three patients involved in these reports. Twenty reports (41 percent) included patient involvement, mainly through protocol review, draft validation, consultation meetings, or qualitative research. Twenty-nine reports (59 percent) had no patient involvement; among these, six of twenty-nine (21 percent) had attempted recruitment but could not implement it due to recruitment or organizational barriers. In reports with involvement, participation represented a small proportion of assessment time and often relied on a single patient. Patient respondents valued their contribution but noted unclear expectations, technical language, and limited feedback.
Conclusions
The protocol proved feasible and valuable for monitoring whether, how, and when patients are involved in HTA. Strengthening planning, recruitment, and feedback will support more meaningful engagement. RedETS provides a scalable model for continuous monitoring in HTA.
The UK is being positioned to become a leader in the field of artificial intelligence (AI), with the government driving the AI Opportunities Action Plan. In line with the government’s push for an AI-driven future, horizon-scanning organizations are leveraging AI and embedding it within their methodological practices. To ensure the transparent, reliable, and responsible use of AI, horizon scanning requires a set of tailored reporting items. However, this is a notable gap in the current methodological landscape.
Methods
This methods communication discusses the current guidelines, policies, and statements around the use of AI relevant to futures and foresight research for health, social care, and life sciences policy and practice. We include stakeholder positions, research funding applications and writing for publication within the discussion and demonstrate how these guidelines relate to horizon scanning practices, with a focus on the common recommendations for reporting AI.
Results
We have utilized the documents to identify and consolidate reporting recommendations into a minimal set of reporting items for AI in horizon scanning. A total of 139 data points were consolidated into 46 reporting items under six categories.
Conclusions
Further work is needed to validate these reporting items, but this interim step toward a robust reporting framework fills an immediate methodological need. We encourage those working in the horizon scanning space to continue to explore and embed AI transparently and responsibly in this rapidly adapting field.
Health technology assessment is emerging in Lebanon, with an increased interest in health economic evaluations (EEs). Despite the importance of the methodological quality of EEs, no study has examined this issue in Lebanon.
Objective
As only methodologically robust health EE can meaningfully inform decision making, this study systematically reviews and critically appraises published full EEs in Lebanon, formulating recommendations to strengthen the quality and consistency of future evaluations within the Lebanese context.
Methods
We searched for full model- and trial-based EEs and cost-minimization analyses (CMAs) on NHSEED, Medline, EMBASE, and CINAHL without language or time restrictions. We followed PRISMA guidelines, narratively synthesized the characteristics, methods, and results of studies, and critically appraised them using CHEC for trial-based evaluations and CMA and CHEC-Extended for model-based evaluations.
Results
Eight studies, published 2012–2025, were included: five model-based, two trial-based, and one CMA. Assessed technologies included screening/vaccination programs, diagnostic tools, nutrition education, e-mental health interventions, and early versus delayed treatment of hepatitis C. Methodological inconsistencies pertained mostly to discounting rates and willingness-to-pay thresholds. Suboptimal quality pertained mainly to model-based evaluations conducted by Lebanese researchers. Common pitfalls included the perspective being unclear; the identification, measurement, and valuation of costs and outcomes; model validation and calibration; sensitivity analyses; and discounting. The trial-based and CMA met more than 80 percent of the criteria.
Conclusion
We identified a limited number of published full EEs in Lebanon and highlighted their major shortcomings. Future work should scale up high-quality EEs in Lebanon, particularly modeling studies, to inform resource allocation.
The use of qualitative research with randomized controlled trials (RCTs) has grown exponentially over the last decade, but little is known about how it is contributing to trial procedures and interventions. This review systematically mapped the value that qualitative research has had in RCTs of drugs and medical devices.
Methods
We searched five electronic databases (MEDLINE, EMBASE, PsycINFO, CINAHL, and ASSIA) and the NIHR Journals Library to identify original, peer-reviewed qualitative research conducted in the context of specific RCTs (pilot or full). Drawing on studies published between January 2019 and December 2020, we identified and classified examples illustrating how qualitative research had contributed to the trial. This created a list of questions qualitative methods can address in RCTs.
Results
Of 207 included studies, only 22 percent explicitly articulated their value. Most frequently reported contributions included: (a) explaining trial findings; (b) ensuring that interventions meet the needs of key stakeholders; and (c) making the trial feasible and viable (e.g., through improved trial design and conduct). A total of 776 examples demonstrating how qualitative methods had enhanced the trial were classified into twenty-seven subcategories. A list of sixty potential questions was developed to assist future research design.
Conclusions
The value of qualitative research in trials is expanding. While qualitative methods have traditionally been associated with complex interventions, this review highlights their relevance to trials involving drugs and devices. Future trials could benefit from expanding the use of qualitative methods to deepen understanding of outcomes, strengthen measurement validity, and capture experiences of conditions.
Pathway models incorporate multiple decision nodes to assess the most cost-effective sequence or the optimal point of introduction of a new technology within a treatment pathway. Pathway models are particularly useful in disease areas such as oncology, where patients may have several lines of therapy. We aimed to review methodologies for modeling and evidence synthesis in pathway models that evaluate the cost-effectiveness of treatment strategies within oncology.
Methods
We designed a search to identify relevant methodological papers and systematic reviews of oncology pathway models that critique their methodological approaches. We also updated a previous review of studies on methods for evidence synthesis to inform pathway models. Best practice recommendations were extracted and summarized.
Results
Nine and five studies were included on methods for model structures and evidence synthesis, respectively. Key themes related to data requirements, including a preference for patient-level model structures and data from multi-line sources. There was limited guidance on alternative model structures in the absence of patient-level data. Multi-state network meta-analysis with flexible survival models was the most appropriate method identified for evidence synthesis; however, due to data limitations, it may be necessary to conduct separate syntheses at each line of therapy.
Conclusions
Data limitations may reduce the potential benefits of pathway models. Further method development is needed for pathway models in decision spaces where individual patient data and sources that cover multiple lines of treatment are not available.
The European Union health technology assessment (HTA) regulation increases pressure on European HTA organizations’ capacity and new domains of expertise continue to emerge quickly in the HTA field. Therefore, this study aimed to identify emerging competencies described in the literature and to update and verify an existing HTA competency framework, encompassing both process-related and domain-specific expertise for conducting HTA.
Methods
Using a scoping review approach, PubMed, Embase, PsycINFO, ERIC, CINAHL, and Web of Science were searched from 1 January 2018 until 13 May 2024. The websites of HTA-related societies were searched on 22 April 2024. Documents describing competencies for HTA professionals were included. Deductive content analysis of the identified competencies was performed, utilizing the competencies from the original framework.
Results
A total of nineteen documents were included, consisting of six competency frameworks, one handbook, and twelve scientific articles. The identified competencies from these documents mapped appropriately to the original competency framework. New competencies within existing domains that emerged were related to organizational sustainability, patient and public involvement, real-world data, interpreting and developing HTA reports, and stakeholder identification. In addition, three new competency domains were identified, which were artificial intelligence use for HTA, environmental aspects, and performance and achievements.
Conclusions
The newly identified competencies and competency domains highlight emerging areas of expertise for HTA professionals and need to be added to the original competency framework. An updated competency framework can support capacity building efforts and the development of training programs to ensure that HTA professionals are well-equipped to address current healthcare challenges.
Ontologies support transparent and reproducible conceptual modeling in Health Technology Assessment (HTA), but their population remains resource-intensive and reliant on expert input. This study evaluates the feasibility, reliability, and methodological implications of using generative artificial intelligence (GenAI) to populate ontology individuals for HTA applications.
Methods
A factorial experimental framework was developed using the Ontology for Simulation Modeling (OSDi) and three HTA-relevant use cases of varying complexity. Two GenAI systems were evaluated under multiple experimental conditions, including prompting strategy, serialization format, and provision of supporting information. Generated ontology individuals were validated by an HTA expert and assessed across four quality dimensions: consistency, relevance, completeness, and adequacy. Multivariate and regression analyses were conducted to examine the effects of experimental factors on quality outcomes and hallucination likelihood.
Results
GenAI systems successfully generated ontology individuals across use cases, although performance varied by quality dimension and experimental condition. Iterative prompting significantly improved completeness, while serialization format strongly influenced reliability, with Turtle serialization associated with substantially lower hallucination likelihood compared with XML. Other factors showed dimension-specific effects, highlighting the multidimensional nature of ontology quality. Errors occurred more frequently in structurally complex ontology components, suggesting a relationship between ontological complexity and generative performance.
Conclusions
GenAI-assisted ontology population can enhance the efficiency and scalability of HTA conceptual modeling, enhancing the agility of HTA agencies in exploratory phases. Its effective use requires structured prompting, appropriate representation formats, and expert validation. Further research should evaluate its impact on HTA decision modeling workflows and validation frameworks.
The rapid evolution of digital health technologies (DHTs) presents distinct challenges for health technology assessment (HTA). Existing HTA frameworks, largely designed for conventional health interventions, may not sufficiently address these unique complexities. This scoping review provides an overview of existing assessment frameworks for DHTs, analyzing their purpose and the guidance they offer within the domains of the EUnetHTA Core Model.
Methods
The review followed the Joanna Briggs Institute methodology and PRISMA-ScR guidelines. The literature was identified through searches in PubMed and Embase, covering publications from 2015 to 2024 in English or German, and was complemented by a manual hand search. The studies were screened and analyzed using Covidence, with data categorized inductively based on the EUnetHTA Core Model domains.
Results
Of 3,576 screened records, 15 met inclusion criteria; an additional 45 frameworks were identified through hand searching, resulting in a total of 60 frameworks. Most frameworks focused on digital health applications (68 percent), while only a few addressed technologies such as artificial intelligence (2 percent). The frameworks primarily provide guidance on assessment, with varying focus on evidence requirements. The domains of the EUnetHTA Core Model were variably represented across the frameworks. Technical characteristics were most frequently addressed, while ethical, legal, and organizational domains received limited attention.
Conclusions
This review highlights the diversity of existing frameworks for DHT assessment. This emphasizes the potential relevance of a future standardized framework that contains explanations of the methodological approach to the assessment of DHTs and is modularly customizable depending on the type of technology.
Patient involvement is recognized as an integral component of health technology assessment (HTA), with patients’ lived experiences offering valuable insights that enhance the relevance, transparency, and quality of healthcare decision-making. In line with a national shift toward patient-centered care, Singapore’s Agency for Care Effectiveness (ACE) established formal processes for patient involvement in HTA in 2021. This paper describes ACE’s structured approach to identifying relevant patient organizations, co-developing processes, and building capacity to support meaningful patient input.
Methods
A stakeholder mapping exercise was undertaken to identify relevant local patient and volunteer organizations by searching the Singapore Charity Portal, hospital websites, search engines, and social media platforms. Identified organizations were screened against predefined criteria and contacted to determine their interest in ACE’s work. A process and methods guide, including survey templates, plain language materials, and training resources were co-developed with local patient organizations, drawing on international best practices, contextualized to local patients’ needs.
Results
ACE identified 106 patient organizations across 20 health conditions. During a pilot initiative between August and December 2022, 82 patients from 10 organizations provided input into 7 HTAs. Sustained participation continued afterwards, with patient testimonials submitted for 85 percent of HTAs in the first year, increasing to 89 percent in the second year.
Conclusions
ACE’s patient involvement processes have improved the relevance and acceptance of HTA recommendations. Ongoing engagement with patient organizations, systematic evaluation of impact, and refinement of processes will be crucial to ensure that patient input continues to inform and advance healthcare decision-making in Singapore.
The overall aim is to understand the practices, views, and needs of health technology assessment (HTA) practitioners worldwide regarding the use of health-related quality of life (HRQoL) data for generating cost-effectiveness evidence.
Methods
We invited HTA practitioners in sixty countries to complete an online survey on their perspectives on the measurement and valuation of health. We performed descriptive analyses of the overall sample, examined response differences across six regions, and pooled responses to open-ended questions for content analysis.
Results
A total of 238 individuals from 45 countries completed the survey, with a mean response number per country of 5.28 (SD: 4.45). Most responses came from public sector employees (seventy-two percent), and ninety percent were involved in cost-effectiveness-related work. The top three most frequently used utility instruments were EQ-5D, SF-6D, and EQ-5D-Y, and the elicitation methods were time trade-off, visual analogue scale, and standard gamble. Health-state preferences of the general public from another country were more frequently used than the preferences of the local public. Common data quality issues were poor sample representativeness and a small sample size of utility data. In Asia and Western Europe, the top-voted research priority was developing utility instruments that capture both healthcare and social care impact. In four regions, developing utility instruments for children was the second-highest research priority.
Conclusions
The survey addressed important knowledge gaps regarding current practices in measuring and valuing HRQoL in HTA and provided insights into HTA practitioners’ views on instruments, methods, and data-related challenges and needs for generating HRQoL evidence.
Guideline development handbooks outline the methodology that authoring organizations use to create public health and clinical practice guidelines (CPGs). We created an Equity Assessment Tool (EquAT) for guideline development handbooks to identify areas of improvement and foster conversations.
Methods
Sequential phases lead to tool development and face/content validation in this mixed-methods study. In phase 1, we reviewed the literature to generate a list of “essential elements” or tasks that are part of guideline development methodology, mapped “essential elements” with relevant equity concepts, and drafted our tool for use in reviewing guideline development handbooks. In phase 2, we surveyed experts for feedback on “essential elements” and explicit language for assessing equity within the tool and refined items. We piloted and finalized the tool based on feedback.
Results
We identified 18 essential elements within five domains of guideline development and created a draft EquAT. Twenty of 25 invited experts responded to the online survey for feedback on the tool. Most experts provided limited feedback, and the most common suggestion was adding clarifying language to the existing tool criteria for assessing equity. Ten experts participated in pilot testing the revised tool. We found a diversity of scores, and potential reasons might be due to the complexity of the tool, differences in equity frameworks, and a variety of expertise. We incorporated their feedback and finalized the tool.
Conclusions
We developed and validated the EquAT, a tool to foster discussion among assessors about the extent of health equity considerations in guideline development handbooks.